Cargando…

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Masaaki, Yajima, Satoshi, Suzuki, Takashi, Oshima, Yoko, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Wang, Hao, Hu, Liubing, Takizawa, Hirotaka, Li, Shu-Yang, Iwadate, Yasuo, Hiwasa, Takaki, Shimada, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983066/
https://www.ncbi.nlm.nih.gov/pubmed/36875818
http://dx.doi.org/10.3892/mi.2023.71
_version_ 1784900465327079424
author Ito, Masaaki
Yajima, Satoshi
Suzuki, Takashi
Oshima, Yoko
Nanami, Tatsuki
Sumazaki, Makoto
Shiratori, Fumiaki
Wang, Hao
Hu, Liubing
Takizawa, Hirotaka
Li, Shu-Yang
Iwadate, Yasuo
Hiwasa, Takaki
Shimada, Hideaki
author_facet Ito, Masaaki
Yajima, Satoshi
Suzuki, Takashi
Oshima, Yoko
Nanami, Tatsuki
Sumazaki, Makoto
Shiratori, Fumiaki
Wang, Hao
Hu, Liubing
Takizawa, Hirotaka
Li, Shu-Yang
Iwadate, Yasuo
Hiwasa, Takaki
Shimada, Hideaki
author_sort Ito, Masaaki
collection PubMed
description WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti-WDR1 antibodies (s-WDR1-Abs) combined with serum levels of anti-CFL1 antibodies (s-CFL1-Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s-WDR1-Ab and s-CFL1-Ab titers were analyzed using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Compared with those of healthy donors, the s-WDR1-Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C-reactive protein levels were significantly associated with overall survival, as determined using the log-rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s-WDR1-Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s-WDR1-Abs or s-CFL1-Abs alone in the Kaplan-Meier test, the patients in the s-WDR1-Ab-positive and s-CFL1-Ab-negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma.
format Online
Article
Text
id pubmed-9983066
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-99830662023-03-04 The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma Ito, Masaaki Yajima, Satoshi Suzuki, Takashi Oshima, Yoko Nanami, Tatsuki Sumazaki, Makoto Shiratori, Fumiaki Wang, Hao Hu, Liubing Takizawa, Hirotaka Li, Shu-Yang Iwadate, Yasuo Hiwasa, Takaki Shimada, Hideaki Med Int (Lond) Articles WD repeat-containing protein 1 (WDR1) regulates the cofilin 1 (CFL1) activity, promotes cytoskeleton remodeling, and thus, facilitates cell migration and invasion. A previous study reported that autoantibodies against CFL1 and β-actin were useful biomarkers for diagnosing and predicting the prognosis of patients with esophageal carcinoma. Therefore, the present study aimed to evaluate the serum levels of anti-WDR1 antibodies (s-WDR1-Abs) combined with serum levels of anti-CFL1 antibodies (s-CFL1-Abs) in patients with esophageal carcinoma. Serum samples obtained from 192 patients with esophageal carcinoma and other solid cancers. And s-WDR1-Ab and s-CFL1-Ab titers were analyzed using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay. Compared with those of healthy donors, the s-WDR1-Ab levels were significantly higher in the 192 patients with esophageal, whereas these were not significantly higher in the samples from patients with gastric, colorectal, lung, or breast cancer. In 91 patients treated with surgery, sex, tumor depth, lymph node metastasis, stage and C-reactive protein levels were significantly associated with overall survival, as determined using the log-rank test, whereas the squamous cell carcinoma antigen, p53 antibody and s-WDR1-Ab levels tended to be associated with a worse prognosis. Although no significant difference was observed in the survival between the positive and negative groups of s-WDR1-Abs or s-CFL1-Abs alone in the Kaplan-Meier test, the patients in the s-WDR1-Ab-positive and s-CFL1-Ab-negative groups exhibited a significantly poorer prognosis in the overall survival analysis. On the whole, the present study demonstrates that the combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies in serum may be a poor prognostic factor for patients with esophageal carcinoma. D.A. Spandidos 2023-01-31 /pmc/articles/PMC9983066/ /pubmed/36875818 http://dx.doi.org/10.3892/mi.2023.71 Text en Copyright: © Ito et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Articles
Ito, Masaaki
Yajima, Satoshi
Suzuki, Takashi
Oshima, Yoko
Nanami, Tatsuki
Sumazaki, Makoto
Shiratori, Fumiaki
Wang, Hao
Hu, Liubing
Takizawa, Hirotaka
Li, Shu-Yang
Iwadate, Yasuo
Hiwasa, Takaki
Shimada, Hideaki
The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title_full The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title_fullStr The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title_full_unstemmed The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title_short The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
title_sort combination of positive anti‑wdr1 antibodies with negative anti‑cfl1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983066/
https://www.ncbi.nlm.nih.gov/pubmed/36875818
http://dx.doi.org/10.3892/mi.2023.71
work_keys_str_mv AT itomasaaki thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT yajimasatoshi thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT suzukitakashi thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT oshimayoko thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT nanamitatsuki thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT sumazakimakoto thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT shiratorifumiaki thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT wanghao thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT huliubing thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT takizawahirotaka thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT lishuyang thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT iwadateyasuo thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT hiwasatakaki thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT shimadahideaki thecombinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT itomasaaki combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT yajimasatoshi combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT suzukitakashi combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT oshimayoko combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT nanamitatsuki combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT sumazakimakoto combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT shiratorifumiaki combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT wanghao combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT huliubing combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT takizawahirotaka combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT lishuyang combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT iwadateyasuo combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT hiwasatakaki combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma
AT shimadahideaki combinationofpositiveantiwdr1antibodieswithnegativeanticfl1antibodiesinserumisapoorprognosticfactorforpatientswithesophagealcarcinoma